Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16402425 | 0.82 | CA2 (0.37) | CA2ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL5078106 | 0.82 | THRB (0.33) | CA2 | |
| SCHEMBL6151164 | 0.82 | CA2 (0.32) | CA2ALDH1A1 | |
| SCHEMBL2325979 | 0.79 | — | — | |
| SCHEMBL27560428 | 0.79 | — | — | |
| SCHEMBL4104149 | 0.79 | — | — | |
| SCHEMBL486188 | 0.79 | — | — | |
| SCHEMBL5081323 | 0.77 | THRB (0.42) | — | |
| SCHEMBL2138458 | 0.77 | — | — | |
| SCHEMBL12261955 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814348-B2 | Oxidizing liquid media for chemical transformations | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-11-14 | — | — | US | claimed |
| CN-112346309-A | Preparation method of durable anti-counterfeiting blue carbon powder | 湖北尚彩新材料科技有限公司 | 2021-02-09 | — | — | CN | claimed |
| WO-2009019219-A2 | METHODS OF USING A SOLVENT OR A FOAM BLOWING AGENT | Solvay (Société Anonyme) (BE) | 2009-02-12 | — | — | WO | claimed |
| EP-0580916-B1 | N(1) substituted pyrazino [2,3-c]-1,2,6-thiadiazine 2,2-dioxides and their use as pharmaceuticals | PRODESFARMA SA (ES) | 1997-03-05 | — | — | EP | claimed |
| EP-0580916-A1 | N(1) substituted pyrazino 2,3-c -1,2,6-thiadiazine 2,2-dioxides and their use as pharmaceuticals | PRODESFARMA, S.A. (ES) | 1994-02-02 | — | — | EP | claimed |
| CN-115108905-B | Method for producing (Z) -trifluoromethaneenol ester by copper-catalyzed regioselective olefination and trifluoromethylation of carboxylic acid | 湖南大学 | 2025-04-08 | — | — | CN | disclosed |
| CN-115710637-B | Extractant and application thereof in extraction of lithium, rubidium and cesium | 中国科学院过程工程研究所 | 2025-03-11 | — | — | CN | disclosed |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-20240058315-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | NOVARTIS AG (CH) | 2024-02-22 | — | — | US | disclosed |
| US-11814348-B2 | Oxidizing liquid media for chemical transformations | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-11-14 | — | — | US | disclosed |
| US-11551827-B2 | Perfluorinated 1-alkoxypropenes in dielectric fluids and electrical devices | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-01-10 | — | — | US | disclosed |
| CN-115108905-A | Method for generating (Z) -trifluoromethane enol ester by copper-catalyzed regioselective olefination and trifluoromethylation of carboxylic acid | 湖南大学 | 2022-09-27 | — | — | CN | disclosed |
| US-5057586-A | Fluoropolymers | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-10-15 | — | — | US | disclosed |
| US-4973714-A | ADDITION POLYMERS, FLUOROPOLYMERS, HEAT RESISTANCE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-11-27 | — | — | US | disclosed |
| US-4810806-A | FROM A HALOETHYL CARBOXYLATE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-03-07 | — | — | US | disclosed |
| EP-0301881-A1 | Halogenated 1,3-dioxolanes and derivatives | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-02-01 | — | — | EP | disclosed |
| US-4343742-A | CYCLIZATION OF MONOETHERS CONTAINING CARBONYL, AMMONIUM OR ALKALI FLUORIDE | HOECHST AKTIENGESELLSCHAFT | 1982-08-10 | — | — | US | disclosed |
| US-4005104-A | CHEMICAL INTERMEDIATE FOR PERFLUOROBIACETYL | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-01-25 | — | — | US | disclosed |
| US-4005104-A | CHEMICAL INTERMEDIATE FOR PERFLUOROBIACETYL | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-01-25 | — | — | US | disclosed |
| US-3985810-A | METALLIC CATALYST; REACTING A CARBOXYLIC ACID FLUORIDE | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11551827-B2 | Perfluorinated 1-alkoxypropenes in dielectric fluids and electrical devices | AFF1, AFF2, AFF4 | CA2 3047/4885ALDH1A1 331/4885POLB 2311/4885 |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | CFTR, OPRK1, CHRM3 | CA2 3580/4885ALDH1A1 2546/4885POLB 2917/4885 |
| US-20240058315-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | CFTR, OPRK1, CHRM3 | CA2 3076/4885ALDH1A1 2914/4885POLB 2724/4885 |
| US-11814348-B2 | Oxidizing liquid media for chemical transformations | HAO2, LPO, DUOX1 | CA2 143/4885ALDH1A1 785/4885POLB 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.